EUVIMEDEUVIMED entdecken
Open Access

Hyperexpression of PTAFR and PF4 as Possible Platelet Risk Biomarkers in Patients With COVID-19

Lívia DE Oliveira Sales, Jean Breno Silveira DA Silva, Flávia Melo Cunha DE Pinho Pessoa, Beatriz Maria Dias Nogueira, Lais Lacerda Brasil DE Oliveira, André Salim Khayat, Manoel Odorico DE Moraes Filho, Maria Elisabete Amaral DE Moraes, Raquel Carvalho Montenegro, Caroline Aquino Moreira-Nunes

In Vivo · 2024

DOI: 10.21873/invivo.13766 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Lívia DE Oliveira Sales und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil. Hauptthemen laut MEDLINE: COVID-19, Platelet Factor 4, Biomarkers, SARS-CoV-2. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: SARS-CoV-2 infection presents different severity levels that suggest the influence of genetic factors on the clinical outcome of the disease. In cases of severe COVID-19, the presence of elevated coagulation markers, increased platelet activation and aggregation and the risk of thrombotic complications are described. Given the participation of these cells in several serious viral infections and their negative role when associated with a prothrombotic response, it is important to understand the mechanistic role of SARS-CoV-2 in platelet physiology. This study evaluated the hyperexpression of platelet-activating factor receptor (PTAFR) and platelet factor 4 (PF4) in unvaccinated and hospitalized patients with COVID-19. PATIENTS AND METHODS: The study included 43 COVID-19 patients stratified according to WHO guidelines. Subsequently, the expression of the PTAFR and PF4 genes were evaluated using the real-time quantitative PCR and their possible correlation with the severity of the disease and clinical variables including hospitalization, outcome, sex, age and laboratory parameters (platelet count, INR and D-dimer). RESULTS: The analysis demonstrated a significant (p 0.05) different between patients stratified according to clinical variables. CONCLUSION: The expression of PTAFR and PF4 suggests an important molecular pathway in the pathophysiology of the disease and may be valuable platelet biomarkers to indicate increased risk in patients with COVID-19 who require hospital care, contributing to personalized intervention strategies and improving their clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Platelet Factor 4BiomarkersSARS-CoV-2Blood PlateletsHumansMaleFemaleMiddle AgedAgedReceptors, G-Protein-CoupledAdultPlatelet Membrane GlycoproteinsPlatelet ActivationSeverity of Illness IndexPlatelet CountRisk Factors

Stichwörter der Autor:innen

COVID-19PF4PTAFRplatelet biomarkersplatelets

Substanzen

Platelet Factor 4Biomarkersplatelet activating factor receptorReceptors, G-Protein-CoupledPlatelet Membrane GlycoproteinsPF4 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil.
  • Clementino Fraga Group, Central Unity, Molecular Biology Laboratory, Fortaleza, CE, Brazil.
  • Department of Biological Sciences, Oncology Research Center, Federal University of Pará, Belém, PA, Brazil.
  • Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil; carolfam@gmail.com.

Zitieren

APA

DE Oliveira Sales, L., DA Silva, J. B. S., DE Pinho Pessoa, F. M. C., Dias Nogueira, B. M., DE Oliveira, L. L. B., Khayat, A. S., DE Moraes Filho, M. O., DE Moraes, M. E. A., Montenegro, R. C., & Moreira-Nunes, C. A. (2024). Hyperexpression of PTAFR and PF4 as Possible Platelet Risk Biomarkers in Patients With COVID-19. In Vivo. https://doi.org/10.21873/invivo.13766

Vancouver

DE Oliveira Sales L, DA Silva JBS, DE Pinho Pessoa FMC, Dias Nogueira BM, DE Oliveira LLB, Khayat AS, et al. Hyperexpression of PTAFR and PF4 as Possible Platelet Risk Biomarkers in Patients With COVID-19. In Vivo. 2024. doi:10.21873/invivo.13766

BibTeX
@article{DEOliveiraSales2024,
  author = {DE Oliveira Sales, Lívia and DA Silva, Jean Breno Silveira and DE Pinho Pessoa, Flávia Melo Cunha and Dias Nogueira, Beatriz Maria and DE Oliveira, Lais Lacerda Brasil and Khayat, André Salim and DE Moraes Filho, Manoel Odorico and DE Moraes, Maria Elisabete Amaral and Montenegro, Raquel Carvalho and Moreira-Nunes, Caroline Aquino},
  title = {Hyperexpression of PTAFR and PF4 as Possible Platelet Risk Biomarkers in Patients With COVID-19},
  journal = {In Vivo},
  year = {2024},
  doi = {10.21873/invivo.13766}
}
Kostenlos starten →